

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

Publication number:

0 571 671 A1

(20)

EUROPEAN PATENT APPLICATION

(21)

Application number: 92304712.0

(51)

Int. Cl.⁵: **A61K 9/00**

(22)

Date of filing: 26.05.92

(43)

Date of publication of application:
01.12.93 Bulletin 93/48

(94)

Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IT LI LU NL PT
SE**

(71)

Applicant: **THE PROCTER & GAMBLE
COMPANY**
One Procter & Gamble Plaza
Cincinnati Ohio 45202(US)

(72)

Inventor: **Koochaki, Patricia Elaine**
9241 Souffle Circle
Cincinnati, Ohio 45242(US)

(74)

Representative: **Brooks, Maxim Courtney et al**
Procter & Gamble (NTC) Limited
Whitley Road
Longbenton
Newcastle-upon-Tyne NE12 9TS (GB)

(54)

A Pharmaceutical composition in powder form.

(57)

A pharmaceutical composition in powder form comprising a drug and a pharmaceutically-acceptable carrier, the carrier comprising a non-ionic cellulose ether derivative and a chitin-derived polymer. The pharmaceutical composition provides a high availability of the active ingredient and displays improved adhesion characteristics.

EP 0 571 671 A1

- This invention relates to a pharmaceutical composition in powder form for application to the nasal mucosa. In particular, it relates to a sustained-release pharmaceutical composition in powder form comprising a drug, a nonionic cellulose ether derivative and a chitin-derived polymer which provides a high availability of the active ingredient, improved adhesion to the nasal mucosa, solves the common problem of "roll-back" commonly associated with spray and drop formulations such as decongestants and prevents the nasty aftertaste of the formulation active ingredient.

Background of the Invention

- Various pharmaceutical preparations for application to the nasal cavity such as nasal ointments, jellies, nose drops and sprays are known in the art. Nasal ointments and jellies are unsatisfactory, however, because it is difficult to apply them to deep parts of the nasal cavity, such as the concha nasalis superior. Nose drops and sprays have the disadvantage, moreover, that it is difficult to retain the active drugs contained therein in the nasal cavity for an extended period of time. In addition, they are not efficient sustained-release formulations.

- In the prior art, attempts have been made to prepare sustained-release formulations for application to the nasal mucosa. US-A-4,226,848 discloses a sustained-release pharmaceutical composition for application to the nasal mucosa containing a drug and a carrier. Sustained-release is achieved by a mechanism in which the pharmaceutical preparation adheres to the nasal mucosa, absorbs the mucus and gradually swells while adhering to the mucosa, and gradually the drug is released from the swollen portion. The composition comprises a mucosa-adhesive polymeric matrix comprising from about 50 % to about 95 % by weight of a cellulose ether and about 50 % to about 95 % by weight of a polymer of acrylic acid.

- EP-A-0,023,359 discloses a sustained-release, powdery pharmaceutical composition for application to the mucosa of the nasal cavity, comprising a drug and a carrier in which at least 90 % of the composition consists of particles having an effective particle diameter of 20 to 250 μm . The composition comprises a lower alkyl ether of cellulose having a viscosity of 5 to 5000 mPa.s and a drug.

- Chitin is widely distributed in nature. It is found in tissue support of crustaceans and insects and chitosan is the deacetylation product thereof. Chitin and chitosan have previously been used in pharmaceutical sustained-release preparations. EP-A-187,703 and US-A-4,814,176 disclose a sustained-release preparation in which a combination of chitin and/or chitosan and an anionic polymer is utilised as a sustained-releasing agent.

- It is an object of the present invention to provide a sustained-release powdery pharmaceutical composition with improved adhesion characteristics which provides a high availability of the active ingredient and which solves the problem of "roll-back" associated with nasal sprays.

Summary of the Invention

- According to one aspect of the present invention, there is provided a pharmaceutical composition in the form of a powder for application to the mucosa of the nasal cavity and which comprises a drug and a pharmaceutically-acceptable carrier, the carrier comprising

- a) from about 90 % to about 10 % by weight thereof of a non-ionic cellulose ether derivative and
- c) from about 10 % to about 90 % by weight thereof of a chitin-derived polymer,

and wherein the total amount of cellulose ether derivative and chitin-derived polymer comprises at least about 50 % by weight of the composition.


Detailed Description of the Invention

In accordance with the present invention a powdery pharmaceutical composition is formed comprising a drug and a carrier. The carrier comprises a non-ionic cellulose ether derivative and a chitin-derived polymer.


- The cellulose ether derivative is present in an amount of about 90 % to about 10 %, preferably from about 85 % to about 45 %, by weight of the carrier. Suitable cellulose ether derivatives include methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and sodium carboxymethyl cellulose, and mixtures thereof. Preferred cellulose ether derivatives include hydroxy C₁ to C₆ alkyl ether celluloses which have an ether substitution degree of from about 0.1 to 6.0, more preferably from about 0.4 to 0.6, highly preferred being hydroxypropylmethyl cellulose (HPMC). HPMC is well known in the pharmaceutical and food industries as a thickener and suspending agent. It has substantially no odour or irritation associated with it and is therefore preferred for application to the nasal mucosa which is particularly sensitive to odour and irritation. Furthermore, HPMC

easily absorbs mucous from the nasal mucosa, thereby giving the pharmaceutical composition effective adhesiveness and flowability on the nasal mucosa. Whilst a variety of grades of the cellulose ether derivative powders may be used it is preferable that a grade of powder should be used which has a viscosity of from about 1 to about 50,000 mPa.s, preferably from about 5 to about 5000 mPa.s (measured at 37°C ± 0.2°C for a 2% aqueous solution of the cellulose ether derivative), in order that the pharmaceutical composition of the present invention forms a viscous, flowable liquid on application to the nasal mucosa.

The chitin-derived polymer in the carrier is present in an amount from 10% to 90%, preferably from 15% to 55%, by weight of the carrier. Suitable chitin-derived polymers include chitin, chitosan and mixtures thereof. Chitin is derived from naturally occurring substances such as in tissues of crustaceans and insects and chitosan is the deacetylation product thereof. The formula of chitin is (1→4)-2-acetamido-2-deoxy-β-D-glucan having the following structure:



Chitosan has the formula (1→4)-2-amino-2-deoxy-β-D-glucan, and has the following structure:



According to the present invention, the preferred chitin-derived polymer is chitosan hydrochloride salt.

Drugs suitable for use in the compositions herein can be selected appropriately according to the disease to which the composition is to be applied. In the present invention the drug is preferably an agent for treating or preventing a nasal disease, preferably a vasoconstrictor or other nasal decongestant. Furthermore the drug should not react with either the cellulose ether derivative or the chitin-derived polymer. Suitable drugs may be in solid or liquid form, preferably solid form.

Examples of such drugs include antipyretic and analgesic agents, antiplogistics, antiarrhythmics, hypotensors, vasodilators, anticholinergics, antiarteriosclerotics, agents for circulatory systems, antitussives, expectorants, ulcer preventives, enzyme preparations, anti-malignants, chemotherapeutic agents, antihistamine agents, enzyme preparations, local anaesthetic agents, and mouth disinfection agents, steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agent, anti-allergic agents, vasoconstrictors, and mixtures thereof.

In compositions to be used for treating or preventing nasal diseases, drugs effective for treatment or prevention of nasal diseases, such as anti-inflammatory agents, antihistamine agents, anticholinergics, anti-allergic agents or vasoconstrictors, are preferred. A highly preferred drug for inclusion in the composition of the present invention is a vasoconstrictor.

Suitable vasoconstrictors for use herein include phenylephrine hydrochloride, ephedrine hydrochloride, tetrahydrozoline hydrochloride, naphthazoline nitrate, oxymetazoline hydrochloride, xylometazoline hydrochloride and tramazoline hydrochloride, preferably oxymetazoline hydrochloride.

In the pharmaceutical composition of the present invention, it is preferred that at least about 85% by weight of the entire particles should have particle size in the range from 5 to 250 μm, preferably from 10 to 120 μm. This particular range is chosen such that a higher proportion of powder composition adheres to the nasal mucosa when applied to the nasal cavity.

The desired particulate form and particle size can be achieved by spray drying a solution of the pharmaceutical composition ingredients. Of all the industrial dryer types available, spray drying is unique in

being able to produce powders of specific particle size and moisture content irrespective of dryer capacity and product heat sensitivity. Spray drying also ensures uniform distribution of the active agent and the carrier. Spray drying consists of four process stages: 1) atomization of feed into a spray, 2) spray-air contact, 3) drying of spray and 4) separation of dry product from the air. Each stage is carried out according to dryer design and operation, and together with the physical and chemical properties of the feed determines the characteristics of the dried product. Spray drying techniques are well known in the art and can be applied in preparing the composition of the invention in known manner.

The present invention is illustrated by the following examples.

Example 1

A powdery pharmaceutical composition of the invention is prepared as follows:

A stoichiometric quantity of chitosan is mixed with purified water and the pH is adjusted to about 4.5 with 37 % hydrochloric acid. The mixture is stirred for about 2 hours until dissolved. The viscosity of the mixture is then adjusted to 550 cps by the addition of water. Stoichiometric quantities of oxymetazoline hydrochloride and hydroxypropylmethyl cellulose are added with stirring until dissolution is complete. The final solution is filtered by passing it through a centre sieve with a 100 μ m filter and the resulting mixture is spray dried at a temperature of 105°C and a minimum pump pressure of 200 bar. In order to achieve the required particle size the powder is passed through a 70 mesh sieve. The final composition of the dry, powdery pharmaceutical composition is as follows:

- 11 % water
- 43.5 % chitosan hydrochloride salt
- 43.5 % hydroxypropylmethyl cellulose
- 2.4% oxymetazoline hydrochloride.

Example 2

A second pharmaceutical composition is prepared using the same method as described in Example 1 having the final dry composition:

- 11 % water
- 17.5 % chitosan hydrochloride salt
- 69.5 % hydroxypropylmethyl cellulose
- 2.4 % oxymetazoline hydrochloride.

The powdery pharmaceutical compositions of the above examples demonstrate improved adhesion characteristics and provide a high availability of active ingredient.

Claims

1. A pharmaceutical composition in the form of a powder for application to the mucosa of the nasal cavity and which comprises a drug and a pharmaceutically-acceptable carrier, the carrier comprising
 - a) from about 90 % to about 10 % by weight thereof of a non-ionic cellulose ether derivative and
 - c) from about 10 % to about 90 % by weight thereof of a chitin-derived polymer,
 and wherein the total amount of cellulose ether derivative and chitin-derived polymer comprises at least about 50 % by weight of the composition.
2. A pharmaceutical composition according to claim 1 wherein the cellulose ether derivative is selected from methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and mixtures thereof.
3. A pharmaceutical composition according to claim 1 wherein said cellulose ether derivative is a hydroxy C₁-C₆ alkyl ether cellulose, preferably hydroxypropylmethyl cellulose.
4. A pharmaceutical composition according to claim 1 wherein said cellulose ether derivative has a viscosity, determined at 37°C \pm 0.2°C for a 2 % aqueous solution, of from about 1 to about 50,000 mPa.s., preferably from about 5 to about 5000 mPa.s.
5. A pharmaceutical composition according to claim 1 having a particle size distribution such that at least about 85 % by weight thereof has a particle size in the range from 5 to 250 μ m, preferably from 10 to

120 μ m.

6. A pharmaceutical composition according to claim 1 wherein the chitin-derived polymer is selected from chitin, chitosan and mixtures thereof.
7. A pharmaceutical composition according to any of claims 1 to 6, wherein the drug is at least one member selected from antipyretic and analgesic agents, antiphlogistics, antiarrhythmics, hypotensors, vasodilators, anticholinergics, antiarteriosclerotics, agents for circulatory systems, antitussives, expectorants, ulcer preventives, enzyme preparations, anti-malignants, chemotherapeutic agents, antihistamine agents, local anesthetic agents, and mouth disinfection agents, steroidal anti-inflammatory agents, nonsteroidal anti-inflammatory agent, anti-allergic agents, vasoconstrictors, and mixtures thereof.
8. A pharmaceutical composition according to any of claims 1 to 7 wherein the drug is an agent for treating or preventing a nasal disease.
9. A pharmaceutical composition according to any of claims 1 to 8, wherein said drug is a vasoconstrictor.
10. A pharmaceutical composition according to claim 9 wherein the vasoconstrictor is selected from oxymetazoline hydrochloride, xylometazoline hydrochloride, phenylephrine hydrochloride, ephedrine hydrochloride, tetrahydrozoline hydrochloride, naphthazoline nitrate, tramazoline hydrochloride.
11. A pharmaceutical composition according to claim 10 wherein the vasoconstrictor is oxymetazoline.
12. A pharmaceutical composition according to any of claims 1 to 11 wherein the carrier comprises
 - a) from about 85 % to about 45 % by weight thereof of the non-ionic cellulose ether derivative, and
 - b) from about 15 % to about 55 % by weight thereof of the chitin-derived polymer.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 92 30 4712

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	DATABASE WPIL Derwent Publications Ltd., London, GB; AN 87061172 & JP-62 016 413 (TEIJIN KK)	1,2,6-8, 12	A61K9/00
Y	* abstract *	3-5,9-11	
Y	EP-A-0 023 359 (TEIJIN LIMITED) * claims 1-10,15 * * page 7, line 1 - line 32 * -----	3-5,9-11	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 10 NOVEMBER 1992	Examiner VENTURA AMAT A.
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : technological background O : non-written disclosure P : intermediate document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		& : member of the same patent family, corresponding document	